バイオシミュレーション市場規模、シェア、動向分析レポート：製品別、用途別、治療分野別、展開モデル別、価格モデル別、最終用途別、地域別、セグメント予測、2025年～2030年

バイオシミュレーション市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のバイオシミュレーション市場規模は2030年までに100億米ドルに達する見込みです。

同市場は2025～2030年にかけてCAGR 17.0％で拡大すると予測されています。市場成長の主要要因としては、慢性疾患の罹患率の増加、医療のデジタル化の進展、臨床検査や研究におけるバイオシミュレーションソリューションの利用などが挙げられます。

急性疾患や慢性疾患が蔓延する中で創薬開発の必要性が高まり、研究開発活動への資金配分が増加したことが、バイオシミュレーションソリューションの採用を後押ししています。加えて、薬剤減少率の高さが臨床検査のコスト増につながるため、インシリコ生物学的アプローチを取り入れることが臨床上の緊急課題となっています。このアプローチは、生物学的相互作用を予測することで薬剤の失敗確率を大幅に低減し、全体的なコストを削減します。

薬剤再発率の上昇、薬剤耐性例の増加、AIDSのような疾患を治療するための薬剤の利用可能性が限られていることから、薬剤開発や創薬のような用途においてバイオシミュレーションの採用が臨床的に急務となっています。

COVID-19パンデミックも市場の成長に大きな影響を与えました。例えばSimulations Plus社は、COVID-19研究に携わるあらゆる組織へのコンサルティング支援を迅速に行うため、2020年3月にStrategiesPlus COVID-19 ACT Programを開始しました。同社は2020年11月現在、同社のビジネスに重大な悪影響はないと宣言しています。しかし、COVID-19の継続的な拡大と影響を受ける国の政府による措置は、サプライチェーンを混乱させ、同社の事業と財務実績に悪影響を及ぼす可能性が高いです。

バイオシミュレーションソフトウェアとサービスに対する需要の急増は、その高いコスト効率にも起因しています。バイオシミュレーションソリューションは、製品開発の初期段階における治験薬の毒性、副作用、有効性をコスト効率よく予測することを可能にし、後期段階における薬剤の再発や有害事象の発生確率を抑制します。

市場参入企業は、市場での競合を維持するため、買収、合併、提携、製品発売など、多くの戦略的イニシアティブに投資しています。例えば、2022年1月、Simulations Plus Inc.は、現行の動物生理学的薬剤動態（PBPK）モデルを検証するため、動物医療企業と提携しました。この資金協力により、同社はGastroPlusプラットフォームに重要な新しい生物種を追加することを目指しました。さらに2021年11月、横河電機はドイツを拠点にバイオプロセスのソフトウェアとサービスを開発・提供するInsilico BIoTechnology AGを買収しました。

バイオシミュレーション市場レポートハイライト

• ソフトウェアが市場を独占し、2024年の売上シェアは62.02%。これは、特定の研究開発要件に対応するアプリケーション固有のソフトウェアが利用可能であることに起因しています。
• 医薬品の発見と開発セグメントは2024年に55.43%の最大市場シェアを占め、これは医薬品開発プロセスの増加によるものです。
• 2024年に最大の収益シェアを占めたのはがん領域でした。腫瘍学では、腫瘍の動態、治療反応、がんの転帰に影響する患者固有の要因を理解する上でバイオシミュレーションが極めて重要です。
• クラウドベースの展開モデルが市場を独占し、2024年には43.00%超の最大収益シェアを占めました。
• ライセンスベースモデルは、2024年に最大の収益シェアを占めました。このモデルの利点は、インフラや開発に多額の投資をすることなく、ユーザーに洗練されたツールへのアクセスを提供することです。
• ライフサイエンス企業が2024年に最大の収益シェアを占めました。これらの企業では、医薬品開発や研究開発における重要なツールとしてバイオシミュレーションソフトウェアの採用が進んでいます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオシミュレーション市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• バイオシミュレーション市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
• COVID-19の影響分析

第4章 バイオシミュレーション市場：製品別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオシミュレーション市場の製品変動分析
• 世界のバイオシミュレーション市場規模と動向分析、製品別、2018～2030年
• ソフトウェア
  • 分子モデリングとシミュレーションソフトウェア
  • 臨床検査設計ソフトウェア
  • PK/PDモデリングとシミュレーションソフトウェア
  • Pbpkモデリングとシミュレーションソフトウェア
  • 毒性予測ソフトウェア
  • その他のソフトウェア
• サービス
  • 契約サービス
  • コンサルティング
  • その他（実装、トレーニング、サポートなど）

第5章 バイオシミュレーション市場：用途別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオシミュレーション市場の用途変動分析
• 世界のバイオシミュレーション市場規模と動向分析、用途別、2018～2030年
• 医薬品の発見と開発
• 疾患モデル
• その他（精密医療、毒物学など）

第6章 バイオシミュレーション市場： 治療分野別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオシミュレーション市場の治療分野変動分析
• 世界のバイオシミュレーション市場規模と動向分析、治療分野別、2018～2030年
• 腫瘍学
• 心血管疾患
• 感染症
• 神経疾患
• その他

第7章 バイオシミュレーション市場：展開モデル別、推定・動向分析

• セグメントダッシュボード
• 世界バイオシミュレーション市場の展開モデル変動分析
• 世界のバイオシミュレーション市場規模と動向分析、展開モデル別、2018～2030年
• クラウドベース
• オンプレミス
• ハイブリッドモデル

第8章 バイオシミュレーション市場：価格モデル別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオシミュレーション市場の価格モデル変動分析
• 世界のバイオシミュレーション市場規模と動向分析、価格モデル別、2018～2030年
• ライセンスベースモデル
• サブスクリプションモデル
• サービスベースモデル
• 従量課金モデル

第9章 バイオシミュレーション市場：最終用途別、推定・動向分析

• セグメントダッシュボード
• 世界のバイオシミュレーション市場の最終用途変動分析
• 世界のバイオシミュレーション市場規模と動向分析、最終用途別、2018～2030年
• ライフサイエンス企業
  • 製薬会社
  • バイオ医薬品企業
  • 医療機器企業
  • CRO/CDMO
• 学術研究機関
• その他（規制当局等）

第10章 バイオシミュレーション市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業の市場ポジション/シェア分析、2024年
• 企業プロファイル/上場企業
  • Certara, USA
  • Dassault Systemes
  • Advanced Chemistry Development
  • Simulation Plus
  • Schrodinger, Inc.
  • Chemical Computing Group ULC
  • Physiomics Plc
  • Rosa &Co. LLC
  • BioSimulation Consulting Inc.
  • Genedata AG
  • Instem Group of Companies
  • PPD, Inc.
  • Yokogawa Insilico BIoTechnology GmbH

List of Tables

• Table 1 List of abbreviations
• Table 2 Global biosimulation market, by region, 2018 - 2030 (USD Million)
• Table 3 Global biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 4 Global biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 5 Global biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 6 Global biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 7 Global biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 8 Global biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 9 North America biosimulation market, by country, 2018 - 2030 (USD Million)
• Table 10 North America biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 11 North America biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 12 North America biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 13 North America biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 14 North America biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 15 North America biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 16 U.S. biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 17 U.S. biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 18 U.S. biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 19 U.S. biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 20 U.S. biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 21 U.S. biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 22 Canada biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 23 Canada biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 24 Canada biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 25 Canada biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 26 Canada biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 27 Canada biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 28 Mexico biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 29 Mexico biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 30 Mexico biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 31 Mexico biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 32 Mexico biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 33 Mexico biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 34 Europe biosimulation market, by country, 2018 - 2030 (USD Million)
• Table 35 Europe biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 36 Europe biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 37 Europe biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 38 Europe biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 39 Europe biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 40 Europe biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 41 UK biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 42 UK biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 43 UK biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 44 UK biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 45 UK biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 46 UK biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 47 Germany biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 48 Germany biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 49 Germany biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 50 Germany biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 51 Germany biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 52 Germany biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 53 France biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 54 France biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 55 France biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 56 France biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 57 France biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 58 France biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 59 Italy biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 60 Italy biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 61 Italy biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 62 Italy biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 63 Italy biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 64 Italy biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 65 Spain biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 66 Spain biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 67 Spain biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 68 Spain biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 69 Spain biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 70 Spain biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 71 Denmark biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 72 Denmark biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 73 Denmark biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 74 Denmark biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 75 Denmark biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 76 Denmark biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 77 Sweden biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 78 Sweden biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 79 Sweden biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 80 Sweden biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 81 Sweden biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 82 Sweden biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 83 Norway biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 84 Norway biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 85 Norway biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 86 Norway biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 87 Norway biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 88 Norway biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 89 Asia Pacific biosimulation market, by country, 2018 - 2030 (USD Million)
• Table 90 Asia Pacific biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 91 Asia Pacific biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 92 Asia Pacific biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 93 Asia Pacific biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 94 Asia Pacific biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 95 Asia Pacific biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 96 China biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 97 China biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 98 China biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 99 China biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 100 China biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 101 China biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 102 Japan biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 103 Japan biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 104 Japan biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 105 Japan biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 106 Japan biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 107 Japan biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 108 India biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 109 India biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 110 India biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 111 India biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 112 South Korea biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 113 India biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 114 South Korea biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 115 South Korea biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 116 South Korea biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 117 South Korea biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 118 South Korea biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 119 South Korea biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 120 Australia biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 121 Australia biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 122 Australia biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 123 Australia biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 124 Australia biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 125 Australia biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 126 Thailand biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 127 Thailand biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 128 Thailand biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 129 Thailand biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 130 Thailand biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 131 Thailand biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 132 Latin America biosimulation market, by country, 2018 - 2030 (USD Million)
• Table 133 Latin America biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 134 Latin America biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 135 Latin America biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 136 Latin America biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 137 Latin America biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 138 Latin America biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 139 Brazil biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 140 Brazil biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 141 Brazil biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 142 Brazil biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 143 Brazil biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 144 Brazil biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 145 Argentina biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 146 Argentina biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 147 Argentina biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 148 Argentina biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 149 Argentina biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 150 Argentina biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 151 MEA biosimulation market, by country, 2018 - 2030 (USD Million)
• Table 152 MEA biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 153 MEA biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 154 MEA biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 155 MEA biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 156 MEA biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 157 MEA biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 158 South Africa biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 159 South Africa biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 160 South Africa biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 161 South Africa biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 162 South Africa biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 163 South Africa biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 164 Saudi Arabia biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 165 Saudi Arabia biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 166 Saudi Arabia biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 167 Saudi Arabia biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 168 Saudi Arabia biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 169 Saudi Arabia biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 170 UAE biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 171 UAE biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 172 UAE biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 173 UAE biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 174 UAE biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 175 UAE biosimulation market, by end use, 2018 - 2030 (USD Million)
• Table 176 Kuwait biosimulation market, by product, 2018 - 2030 (USD Million)
• Table 177 Kuwait biosimulation market, by application, 2018 - 2030 (USD Million)
• Table 178 Kuwait biosimulation market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 179 Kuwait biosimulation market, by deployment model, 2018 - 2030 (USD Million)
• Table 180 Kuwait biosimulation market, by pricing model, 2018 - 2030 (USD Million)
• Table 181 Kuwait biosimulation market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market formulation & validation
• Fig. 4 Biosimulation market: Market outlook
• Fig. 5 Biosimulation market: Segment outlook
• Fig. 6 Biosimulation market: Competitive landscape outlook
• Fig. 7 Parent market outlook
• Fig. 8 Biosimulation market driver impact
• Fig. 9 Biosimulation market restraint impact
• Fig. 10 Biosimulation market: Product outlook and key takeaways
• Fig. 11 Biosimulation market: Product movement analysis
• Fig. 12 Software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 13 Molecular modeling & simulation software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 14 Clinical trial design software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 PK/PD modeling and simulation software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Pbpk modeling and simulation software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Toxicity prediction software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Other software market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Services market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 20 Contract services market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 21 Consulting services market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Other services market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Biosimulation market: Application outlook and key takeaways
• Fig. 24 Biosimulation market: Application movement analysis
• Fig. 25 Drug discovery & development market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Disease modeling market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Biosimulation market: Therapeutic area outlook and key takeaways
• Fig. 29 Biosimulation market: Therapeutic area movement analysis
• Fig. 30 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Cardiovascular disease modeling market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Infectious disease modeling market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Neurological disorders modeling market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Biosimulation market: Deployment model outlook and key takeaways
• Fig. 36 Biosimulation market: Deployment model movement analysis
• Fig. 37 Cloud-based market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 On-premises market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Hybrid market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Biosimulation market: Pricing model outlook and key takeaways
• Fig. 41 Biosimulation market: Pricing model movement analysis
• Fig. 42 License-based model market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Subscription-based model market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Service-based model market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Pay-per-use model market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Biosimulation market: End use outlook and key takeaways
• Fig. 47 Biosimulation market: End use movement analysis
• Fig. 48 Life Science companies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Pharmaceutical companies market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 50 Biopharma companies market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 51 Medical device companies market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 52 CROs/CDMOs market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 53 Academic institutions market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Others market estimates and forecasts,2018 - 2030 (USD Million)
• Fig. 55 Global biosimulation market: Regional outlook and key takeaways
• Fig. 56 Global biosimulation market: Regional movement analysis
• Fig. 57 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 58 Key country dynamics
• Fig. 59 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 60 Key country dynamics
• Fig. 61 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Key country dynamics
• Fig. 66 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Key country dynamics
• Fig. 68 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Key country dynamics
• Fig. 70 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Key country dynamics
• Fig. 72 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Key country dynamics
• Fig. 74 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 Key country dynamics
• Fig. 76 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Key country dynamics
• Fig. 78 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Key country dynamics
• Fig. 80 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 81 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 86 Key country dynamics
• Fig. 87 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 88 Key country dynamics
• Fig. 89 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Key country dynamics
• Fig. 91 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Key country dynamics
• Fig. 93 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 95 Key country dynamics
• Fig. 96 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 97 Key country dynamics
• Fig. 98 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 100 Key country dynamics
• Fig. 101 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 102 Key country dynamics
• Fig. 103 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 104 Key country dynamics
• Fig. 105 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 106 Key country dynamics
• Fig. 107 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Biosimulation Market Growth & Trends:

The global biosimulation market size is expected to reach USD 10.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 17.0% from 2025 to 2030. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has increased the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing overall costs.

A rise in drug relapse rates, drug resistance cases, and the limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market growth. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in COVID-19 research. The company declared that as of November 2020, its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by governments of affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during the early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market players are investing in many strategic initiatives, such as acquisitions, mergers, partnerships, and product launches, to maintain a competitive edge in the market. For instance, in January 2022, Simulations Plus Inc. collaborated with an animal health company for validating current animal physiologically based pharmacokinetic (PBPK) models. With this funded collaboration, the company aimed to add a critical new species to its GastroPlus platform. Moreover, in November 2021, Yokogawa Electric Corporation acquired Insilico Biotechnology AG, a Germany-based company that develops and provides bioprocess software and services.

Biosimulation Market Report Highlights:

• Software dominated the market, with a revenue share of 62.02% in 2024. This can be attributed to the availability of application-specific software catering to specific research and development requirements.
• The drug development segment held the largest market share of 55.43% in 2024, driven by the increasing number of drug development processes.
• Oncology held the largest revenue share in 2024. In oncology, biosimulation is crucial in understanding tumor dynamics, treatment responses, and patient-specific factors influencing cancer outcomes.
• Cloud-based deployment model dominated the market and held the largest revenue share of over 43.00% in 2024 and is expected to grow at the fastest CAGR during the forecast period.
• License-based model held the largest revenue share in 2024. The advantage of this model is that it provides users with access to sophisticated tools without the need for substantial investments in infrastructure or development.
• Life science companies accounted for the largest revenue share in 2024. These companies are increasingly adopting biosimulation software as a critical tool in drug development and research.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Segment
  • 1.2.2. Application Segment
  • 1.2.3. Therapeutic Area Segment
  • 1.2.4. Deployment Model Segment
  • 1.2.5. Pricing Model Segment
  • 1.2.6. End Use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Biosimulation Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of chronic diseases
    • 3.2.1.2. Growing demand for personalized medicine
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with biosimulation technology and software
    • 3.2.2.2. Stringent regulatory requirements
• 3.3. Biosimulation Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
    • 3.3.2.6. Social Landscape
• 3.4. COVID-19 Impact Analysis

Chapter 4. Biosimulation Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Biosimulation Market Product Movement Analysis
• 4.3. Global Biosimulation Market Size & Trend Analysis, by Product, 2018 - 2030 (USD Million)
• 4.4. Software
  • 4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Molecular Modeling & Simulation Software
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Clinical Trial Design Software
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. PK/PD Modeling and Simulation Software
    • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.5. Pbpk Modeling and Simulation Software
    • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.6. Toxicity Prediction Software
    • 4.4.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.7. Other Software
    • 4.4.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 4.5. Services
  • 4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.2. Contract Services
    • 4.5.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.3. Consulting
    • 4.5.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5.4. Other (Implementation, Training, & Support, etc.)
    • 4.5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Biosimulation Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Biosimulation Market Application Movement Analysis
• 5.3. Global Biosimulation Market Size & Trend Analysis, by Application, 2018 - 2030 (USD Million)
• 5.4. Drug Discovery & Development
  • 5.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.5. Disease Modeling
  • 5.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 5.6. Other (Precision Medicine, Toxicology, etc.)
  • 5.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Biosimulation Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Biosimulation Market Therapeutic Area Movement Analysis
• 6.3. Global Biosimulation Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.5. Cardiovascular Disease
  • 6.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.6. Infectious Disease
  • 6.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.7. Neurological Disorders
  • 6.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 6.8. Others
  • 6.8.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Biosimulation Market: Deployment Model Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Biosimulation Market Deployment Model Movement Analysis
• 7.3. Global Biosimulation Market Size & Trend Analysis, by Deployment Model, 2018 - 2030 (USD Million)
• 7.4. Cloud-based
  • 7.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 7.5. On-premises
  • 7.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 7.6. Hybrid Model
  • 7.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Biosimulation Market: Pricing Model Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Global Biosimulation Market Pricing Model Movement Analysis
• 8.3. Global Biosimulation Market Size & Trend Analysis, by Pricing Model, 2018 - 2030 (USD Million)
• 8.4. License-based Model
  • 8.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 8.5. Subscription-based Model
  • 8.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 8.6. Service-based Model
  • 8.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 8.7. Pay Per Use Model
  • 8.7.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Biosimulation Market: End Use Estimates & Trend Analysis

• 9.1. Segment Dashboard
• 9.2. Global Biosimulation Market End Use Movement Analysis
• 9.3. Global Biosimulation Market Size & Trend Analysis, by End Use, 2018 - 2030 (USD Million)
• 9.4. Life Science Companies
  • 9.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.2. Pharmaceutical Companies
    • 9.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.3. Biopharma Companies
    • 9.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.4. Medical Device Companies
    • 9.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.5. CROs/CDMOs
    • 9.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 9.5. Academic Research Institutions
  • 9.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
• 9.6. Others (Regulatory Authorities, etc.)
  • 9.6.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Biosimulation Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2024 & 2030
• 10.2. Regional Market Dashboard
• 10.3. Market Size & Forecasts Trend Analysis, 2018 - 2030:
• 10.4. North America
  • 10.4.1. U.S.
    • 10.4.1.1. Key country dynamics
    • 10.4.1.2. Regulatory framework
    • 10.4.1.3. Competitive scenario
    • 10.4.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.4.2. Canada
    • 10.4.2.1. Key country dynamics
    • 10.4.2.2. Regulatory framework
    • 10.4.2.3. Competitive scenario
    • 10.4.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.4.3. Mexico
    • 10.4.3.1. Key country dynamics
    • 10.4.3.2. Regulatory framework
    • 10.4.3.3. Competitive scenario
    • 10.4.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 10.5. Europe
  • 10.5.1. UK
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.2. Germany
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.3. France
    • 10.5.3.1. Key country dynamics
    • 10.5.3.2. Regulatory framework
    • 10.5.3.3. Competitive scenario
    • 10.5.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.4. Italy
    • 10.5.4.1. Key country dynamics
    • 10.5.4.2. Regulatory framework
    • 10.5.4.3. Competitive scenario
    • 10.5.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.5. Spain
    • 10.5.5.1. Key country dynamics
    • 10.5.5.2. Regulatory framework
    • 10.5.5.3. Competitive scenario
    • 10.5.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.6. Norway
    • 10.5.6.1. Key country dynamics
    • 10.5.6.2. Regulatory framework
    • 10.5.6.3. Competitive scenario
    • 10.5.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.7. Sweden
    • 10.5.7.1. Key country dynamics
    • 10.5.7.2. Regulatory framework
    • 10.5.7.3. Competitive scenario
    • 10.5.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.5.8. Denmark
    • 10.5.8.1. Key country dynamics
    • 10.5.8.2. Regulatory framework
    • 10.5.8.3. Competitive scenario
    • 10.5.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 10.6. Asia Pacific
  • 10.6.1. Japan
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.2. China
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.3. India
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.4. Australia
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.5. South Korea
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.6.6. Thailand
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 10.7. Latin America
  • 10.7.1. Brazil
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.7.2. Argentina
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 10.8. MEA
  • 10.8.1. South Africa
    • 10.8.1.1. Key country dynamics
    • 10.8.1.2. Regulatory framework
    • 10.8.1.3. Competitive scenario
    • 10.8.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8.2. Saudi Arabia
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8.3. UAE
    • 10.8.3.1. Key country dynamics
    • 10.8.3.2. Regulatory framework
    • 10.8.3.3. Competitive scenario
    • 10.8.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 10.8.4. Kuwait
    • 10.8.4.1. Key country dynamics
    • 10.8.4.2. Regulatory framework
    • 10.8.4.3. Competitive scenario
    • 10.8.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Company/Competition Categorization
• 11.2. Strategy Mapping
• 11.3. Company Market Position/Share Analysis, 2024
• 11.4. Company Profiles/Listing
  • 11.4.1. Certara, USA
    • 11.4.1.1. Company overview
    • 11.4.1.2. Financial performance
    • 11.4.1.3. Product benchmarking
    • 11.4.1.4. Strategic initiatives
  • 11.4.2. Dassault Systemes
    • 11.4.2.1. Company overview
    • 11.4.2.2. Financial performance
    • 11.4.2.3. Product benchmarking
    • 11.4.2.4. Strategic initiatives
  • 11.4.3. Advanced Chemistry Development
    • 11.4.3.1. Company overview
    • 11.4.3.2. Financial performance
    • 11.4.3.3. Product benchmarking
    • 11.4.3.4. Strategic initiatives
  • 11.4.4. Simulation Plus
    • 11.4.4.1. Company overview
    • 11.4.4.2. Financial performance
    • 11.4.4.3. Product benchmarking
    • 11.4.4.4. Strategic initiatives
  • 11.4.5. Schrodinger, Inc.
    • 11.4.5.1. Company overview
    • 11.4.5.2. Financial performance
    • 11.4.5.3. Product benchmarking
    • 11.4.5.4. Strategic initiatives
  • 11.4.6. Chemical Computing Group ULC
    • 11.4.6.1. Company overview
    • 11.4.6.2. Financial performance
    • 11.4.6.3. Product benchmarking
    • 11.4.6.4. Strategic initiatives
  • 11.4.7. Physiomics Plc
    • 11.4.7.1. Company overview
    • 11.4.7.2. Financial performance
    • 11.4.7.3. Product benchmarking
    • 11.4.7.4. Strategic initiatives
  • 11.4.8. Rosa & Co. LLC
    • 11.4.8.1. Company overview
    • 11.4.8.2. Financial performance
    • 11.4.8.3. Product benchmarking
    • 11.4.8.4. Strategic initiatives
  • 11.4.9. BioSimulation Consulting Inc.
    • 11.4.9.1. Company overview
    • 11.4.9.2. Financial performance
    • 11.4.9.3. Product benchmarking
    • 11.4.9.4. Strategic initiatives
  • 11.4.10. Genedata AG
    • 11.4.10.1. Company overview
    • 11.4.10.2. Financial performance
    • 11.4.10.3. Product benchmarking
    • 11.4.10.4. Strategic initiatives
  • 11.4.11. Instem Group of Companies
    • 11.4.11.1. Company overview
    • 11.4.11.2. Financial performance
    • 11.4.11.3. Product benchmarking
    • 11.4.11.4. Strategic initiatives
  • 11.4.12. PPD, Inc.
    • 11.4.12.1. Company overview
    • 11.4.12.2. Financial performance
    • 11.4.12.3. Product benchmarking
    • 11.4.12.4. Strategic initiatives
  • 11.4.13. Yokogawa Insilico Biotechnology GmbH
    • 11.4.13.1. Company overview
    • 11.4.13.2. Financial performance
    • 11.4.13.3. Product benchmarking
    • 11.4.13.4. Strategic initiatives